Analyst Ratings February 3, 2026

UBS Keeps Buy Rating on Coca-Cola Ahead of Q4 Results, Cites Durable Growth Path

Analyst holds $82 target as Coca-Cola posts low volatility and steady financial health ahead of February earnings

By Leila Farooq KO
UBS Keeps Buy Rating on Coca-Cola Ahead of Q4 Results, Cites Durable Growth Path
KO

UBS reiterated a Buy rating and an $82 price target on Coca-Cola (NYSE:KO) ahead of the company's fourth-quarter earnings report scheduled for February 10. The bank highlights Coca-Cola's steady organic growth trajectory and low share-price volatility, while noting valuation stretches relative to large-cap peers. Management changes, shifting consumer demand in protein products, upcoming dietary guidance, and a potential premium-coffee acquisition by Luckin Coffee were also flagged in recent developments.

Key Points

  • UBS maintained a Buy rating and an $82.00 price target on Coca-Cola ahead of its Q4 earnings report scheduled for February 10.
  • Analyst Peter Grom forecasts Q4 EPS of $0.56, slightly below the Visible Alpha consensus of $0.57, while expecting continued mid-single-digit organic growth and an "on-algorithm" year.
  • Coca-Cola shows low share-price volatility with a five-year beta of 0.39, a 2.92 InvestingPro financial health score, and a 2.71% dividend yield; however, the stock trades at a premium of over 20% to large-cap peers.

UBS has reaffirmed its Buy recommendation on Coca-Cola (NYSE:KO) and kept an $82.00 price target as the beverage company prepares to release fourth-quarter results on February 10. The stock was trading at $76.84 at the time of UBS's note, reflecting a 22.42% gain over the past year and a recent move past its 52-week high. InvestingPro data cited by UBS shows Coca-Cola carries a "GOOD" overall financial health score of 2.92.

In his note, UBS analyst Peter Grom projects fourth-quarter earnings per share of $0.56, narrowly below the Visible Alpha consensus of $0.57. Despite the slight miss versus consensus, Grom continues to expect "another quarter of +MSD organic growth," and describes initial company guidance as pointing to "another on-algorithm year ahead."

The firm highlighted Coca-Cola's consistency as a distinguishing feature, calling such steady performance "a rarity across our coverage universe." That steadiness is reflected in the company's low five-year beta of 0.39. InvestingPro further notes that the stock "generally trades with low price volatility," a point the research service lists among several ProTips aimed at investors seeking additional perspective.

UBS also addressed investor concerns around valuation. Coca-Cola is trading at a premium of over 20% compared with large-cap multinational peers, well above its five-year historical average premium that the note places in the high single digits. The shares currently carry a price-to-earnings ratio of 25.47, while the PEG ratio sits at 0.98. The company also yields 2.71% in dividends, offering income in addition to prospective capital gains.

Despite the relative premium, UBS judges that "the risk/reward skews to the upside," pointing to what it describes as a "clear path to strong +MSD top line/+HSD EPS growth." InvestingPro's Fair Value assessment suggests the stock appears slightly overvalued at current levels, though analyst targets indicate room for additional upside. The bank's deeper analysis of Coca-Cola is available in the firm's Pro Research Report covering the company's financials and outlook.


Several corporate and industry developments were also noted. Coca-Cola announced a slate of leadership changes alongside the rating, including the appointment of Henrique Braun as CEO effective March 31, 2026. Manolo Arroyo will lead Customer and Commercial Leadership, and Sedef Salingan Sahin has been named Chief Digital Officer.

In consumer-product linkages, UBS noted that BellRing Brands has benefited from comments by Coca-Cola's CEO, James Quincey, highlighting increasing demand for protein products. BellRing, which owns Premier Protein and Dymatize, is cited as a direct beneficiary of that trend.

Broader policy and market items were also referenced. The Trump administration is set to recommend that Americans limit sugar intake to 10 grams per meal in upcoming dietary guidelines, placing emphasis on reducing added sugars, particularly for children, and advising avoidance of highly processed foods. Separately, Luckin Coffee is reportedly considering a bid for Nestle's Blue Bottle Coffee as part of a strategy to expand in the premium coffee segment, backed by Centurium Capital.

UBS's stance combines appreciation for Coca-Cola's predictable top-line trajectory and low volatility with acknowledgement of valuation pressures and other market forces that investors are weighing ahead of the company's quarterly report.

Risks

  • Valuation premium: Coca-Cola trades at a premium of over 20% versus large-cap multinationals, well above its five-year historical average premium in the high single digits - this impacts equity investors in the consumer staples and broader large-cap market.
  • Earnings risk: UBS projects Q4 EPS of $0.56, slightly under the Visible Alpha consensus of $0.57, indicating upside could be constrained if results miss expectations - this affects equity performance in consumer staples.
  • Regulatory/nutrition guidance: Upcoming dietary guidance recommending limits on sugar intake to 10 grams per meal could influence consumer behavior and category demand, affecting beverage and packaged-food sectors.

More from Analyst Ratings

Freedom Capital Upholds Sell on ExxonMobil, Keeps $123 Target Despite Strong Ops Feb 3, 2026 Freedom Capital Keeps Buy on Flexsteel After Strong Q2; $54 Price Target Intact Feb 3, 2026 UBS Lifts ExxonMobil Price Target to $171 After Q4 Results Amid Operational Headwinds Feb 3, 2026 UBS Stays Bullish on Tenet as Conifer Ownership and Contract Terms Shift Feb 3, 2026 UBS Sticks With Neutral on Crocs as Market Sentiment Skews Bearish Feb 3, 2026